Research conducted by CPhI Worldwide, the world’s largest pharmaceutical event, ranks Germany as Europe’s preeminent pharma industry. The data was drawn from the CPhI Annual Report and includes opinions from over 350 international pharma companies. CPhI Worldwide, organised by Informa Markets, is held at Messe Frankfurt on 5-7 November.

The CPhI Pharma Index is the only annually produced perception ranking of the world’s top-performing countries. It provides vital insights into the world’s leading pharma economies across all attributes and indicates which markets have the greatest business prospects and growth potential.

The results see Germany consolidate its status as an elite pharmaceutical market, finishing ahead of its European rivals in API Manufacturing (7.88), competitiveness (6.48), innovation (7.49) finished product manufacturing (8.02), and growth potential (6.92).

One of the most notable trends is the sudden rise in anticipated growth potential for Germany in 2019/2020, increasing by 11% from 2018

The research’s authors attribute the shifting European outlook over the last couple of years to wider macro changes, as well as the continued strength of European pharma. Germany is perceived to be reaping a ‘Brexit boost’ in its medium-term growth potential – with an equal drop in the UK scores directly correlating to the increases seen in Germany’s.

Orhan Caglayan, Brand Director at CPhI Worldwide, commented: “It is no surprise that Germany has again emerged as a global pharmaceutical leader. However, the country has further increased its score, suggesting it has consolidated its position as Europe’s top pharma industry."

The full CPhI Pharma Market Index will be made available later in the year within its 2019 Annual Industry Report.

Source: www.cleanroomtechnology.com